Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E)

Authors :: Harry J.M. Groen
William Pao
Scott N. Gettinger
Vikram K. Chand
Bushi Wang
Egbert F. Smit
R. Camidge
Yelena Y. Janjigian
D. Schnell
Leora Horn
Source :: International Journal of Radiation Oncology*Biology*Physics. 90:S39-S40
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Radiation
Cetuximab
business.industry
Afatinib
Gefitinib
Acquired resistance
Internal medicine
medicine
Radiology, Nuclear Medicine and imaging
In patient
Erlotinib
business
medicine.drug

Tools